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Silver-hydroxyapatite nanocomposites as bactericide 
and fungicide materials 
 
Silver-hydroxyapatite nanocomposites containing 1 wt% of metallic silver have been 
obtained by a colloidal chemical route and subsequent chemical reduction process. The 
silver nanoparticles are supported onto the HA surface without a high degree of 
agglomeration. The bactericidal effect against common Gram-positive and Gram-
negative bacteria, as well as antifungal activity against yeast have been investigated. 
The results indicated a high antimicrobial activity for E. coli, M. Luteus and I. 
Orientalis, so this material can be a promising antimicrobial biomaterial for implant and 
reconstructive surgery, among other applications. 
 
Keywords: Hydroxyapatite, silver, nanocomposite, antimicrobial, antibacterial, 
antifungal. 
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1. Introduction 
There is a necessity for replacing bone substance which has been lost due to 
traumatic or nontraumatic events [1]. The development of advanced materials for 
biomedical applications is among the most important problems facing modern materials 
engineering [2]. In the field of orthopaedic applications, metals have been widely used 
for major load-bearing, but there are, however, various problems related to metallic 
materials in the human body due to corrosion, wear and/or negative tissue reaction [1].  
One alternative is the group of bioceramic materials, where the hydroxyapatite 
(Ca10(PO4)6(OH)2, HA) stands out. This calcium phosphate is widely used as implants, 
drug carriers, and bone tissue engineering scaffolds, because its phase structure and 
chemical composition are similar to the mineral phase of hard tissue in the body [3]. 
Furthermore, HA has the ability to form chemical bond with bone tissue in vivo (i.e., 
bioactivity) and to lead bone tissue growth on the implants (i.e., osteoconductivity) [4]. 
So, when the implant based in HA is in direct contact with pre-existing bone is manifest 
the capacity to support bone ingrowth [5]. 
Although success rates of these kinds of implants are dependent on bone-implant 
osteointegration, the success and long-term survival of the implants are also dependent 
on the prevention of bacterial infection after implant placement [6]. The infection rates 
of total joint hip arthroplasties have been reported to range between 0.5 and 3.0% in 
primary total hip arthroplasty [7,8]. Infection is a devastating reason which severely 
affects patient outcome, reduces the lifespan of the prosthesis, and increases prosthesis 
failure rates. It accounts for an enormous medical costs, increased morbidity, and 
decreased patient satisfaction [9]. 
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One common and accepted strategy to treat and prevent infections associated 
with orthopedic implants is to deliver antibiotics in a controlled manner at the site of 
implantation in order to administer high local doses without exceeding the systemic 
toxicity of these drugs [10-13]. However, the capacity of certain bacterial strains to 
develop resistance against antibiotics has aroused an increasing interest for the 
controlled delivery of other antibacterial agents with a broader activity and low 
incidence of resistance. Such agents could be certain metals like silver or zinc, which 
are an alternative to avoid the formation of adhesive bacterial films [14,15]. 
Silver, known as a disinfectant for many years, has a broad spectrum of 
antibacterial activity. The silver particles bind to the bacterial cell wall and cell 
membrane and inhibit the respiration process [16,17]. The nanoparticles release silver 
ions in the bacterial cells, which enhance their bactericidal activity [18,19]. The 
common bacterial strains involved in implant-associated infections are included in the 
pathogens that silver can eliminate. Likewise, it is well reported the lack of toxicity of 
low concentrations of silver for the mammalian cells[20,21].The silver nanoparticles 
show efficient antimicrobial properties compared to other silver salts due to their 
extremely large surface area and less solubility, which provides better contact with 
microorganisms. Silver nanoparticles in most studies are suggested to be non-toxic in 
low concentrations, but in high concentration could have toxic effects. 
In this work, a nano-nano composite of HA with a very low content of silver 
nanoparticles on its surface is presented (1 wt% Ag). The ceramic support avoids the 
metal agglomeration and keeps the nanoparticles attached. The antimicrobial benefits of 
the composite were evaluated against Gram-positive and Gram–negative bacteria, and 
the antifungal activity was evaluated against yeast. 
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2. Experimental procedure 
HA nanopowders with an average size (d50) of 137 nm prepared in situ in the 
laboratory were used as raw material for the matrix of the composite. This powder was 
synthesised by a sol-gel route using triethylphosphite and calcium nitrate tetrahydrate as 
precursors. This process is described detailed in a previous work [22]. 
Suspensions containing 9 wt% solids with 1 wt% of an alkali-free organic 
polyelectrolyte as a surfactant (Dolapix CE-64) were prepared in distilled water as the 
liquid medium. The suspension was homogenised by milling with alumina balls in 
polyethylene containers for 24 hours. The pH was adjusted to 7 by adding drop-wise a 
0.1 N NaOH aqueous solution under stirring. Then, AgNO3 (Riedel-de Haën) in 
aqueous solution was added as a precursor to obtain a HA/nAg composite containing 1 
wt% of metallic silver. The reduction of the cation Ag
+
 and precipitation of Ag
0
 was 
carried out employing sodium borohydride (NaBH4, Sigma-Aldrich). The stequiometric 
molar relation between the NaBH4 and the Ag
+
 is 1:8 according to the next reactions: 
 






H7)OH(BAg8OH3BHAg 8
e8H7)OH(BOH3BH
Ag 1e Ag 8
3
0
24
324
0-
 
An excess of NaBH4 was added to guarantee the total reduction of silver. This 
reducing agent was dropped quickly into the stirred mixture with the HA and the silver 
salt. Finally, the suspension was filtered and washed twice with distilled water. The 
resulting powder was dried at 60ºC. 
 The particle size distribution was determined in a Coulter LS 13320 particle size 
analyser equipped with a laser source (=750 nm). X-ray powder diffraction (XRD) 
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patterns were registered using a Bruker D8 Advance diffractometer with a 
CuKradiation source at a scan speed of 0.5 degrees/minute and a step scan of 0.02º. 
Transmission electron microscopy (TEM) images were recorded on a Jeol 2000 FXII 
instrument and a JEM 2100F using the HAADF-STEM technique, both operating at 200 
kV. 
The silver concentration in the final material was analyzed using an atomic 
absorption spectrometer Varian SpectrAA 220-FS, with an air/acetylene flame 85/15 
and a light source of λ= 328.1 nm. The sample was previously dissolved in HNO3. 
Antibacterial tests were performed to investigate the effect of the HA/nAg 
powder on three different microorganisms: Escherichia coli JM 110 (Gram-negative 
bacteria), Micrococcus luteus (Gram-positive bacteria) and Issatchenkia orientalis 
(yeast). The three different microorganisms were incubated in a liquid media overnight 
at 37ºC. After that, 10 L from each culture were diluted to 5 mL, using the suitable 
media, and cultured at 37ºC for 6 h. The media used were Luria Bertani (LB) for 
Escherichia coli JM 110 and for Micrococcus luteus; the media was yeast extract 
dextrose (YEPD) for Issatchenkia orientalis. Then, 10 μL from the cultures were diluted 
in 1 mL of nutrient, according to the microorganism used. Subsequently, 150 L of an 
aqueous suspension of HA/nAg composite (20 wt%) were added, obtaining a final 
concentration of silver in each culture of 0.026 wt%. A silver free media (a mixture of 
water containing the corresponding nutrient according to the microorganism tested: LB 
or YEPD) was used as control. The microorganisms were tested for viability after 
culture on appropriate dilution from the corresponding cultures. The inoculums were 
incubated at 30ºC with horizontal shake until 72 h. The number of colonies was counted 
every 24 h. 
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3. Results and discussion 
According to the X-ray diffraction patterns recorded in Fig. 1, both the HA 
powder and the HA/nAg nanocomposite powder obtained present a good degree of 
crystallization. In the case of the nanocomposite, the Bragg’s reflections corresponding 
to metallic silver are visible (2θ = 38.2º and 44.4º, JCPDS 87-0720). 
The parameters corresponding to the initial particle size distributions of the 
starting HA powders expressed in terms of d50 and d90 were 117 nm and 155 nm, 
respectively. 
By comparing this granulometric analysis with the SEM image of the composite 
shown in Fig. 3, it is possible to infer that the powder matrix size continues in the same 
nanometric range after the metallic particles addition. 
The silver concentration was analyzed in the final material to determine the 
efficiency of the deposition process. The efficiency was defined with respect to the 
theoretical concentration with the equation [1]: 
100
C
C
t
s        Eq. [1] 
where η is the efficiency of the deposition process, Cs is the final concentration in the 
sample, and Ct is the theoretical concentration of Ag in the sample. As the value for Cs 
is 0.93%, the efficiency of the deposition was found to be η=93%. This value indicates 
that only a small percentage of Ag was lost during the washing process of the sample. 
At that stage, the eliminated material was mainly formed by subproducts of the 
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precursors and dispersant, practically the total amount of silver is attached onto the HA 
surface.  
TEM images show in Fig. 4 a size distribution of globular-shape silver particles 
that ranges between less than 10 nm and 50 nm, with hardly any agglomerates. This is 
in agreement with the particle size of 16 nm, diameter calculated by the Scherrer 
equation.  
It is well reported that silver nanoparticles display a surface plasmon resonance 
around 400 nm. However, depending on the environment of the nanoparticles and their 
size and shape distribution, the precise position and shape of the band may vary [23,24]. 
As it can be observed in the UV-VIS spectrum in Fig. 5A, the light absorption maxima 
corresponding to the surface plasmon resonance of the HA/nAg powder is located at 
426 nm. As a consequence, the powder shows a dark greenish grey colour (Fig. 5B). 
The colloidal silver solutions are yellow when the nanoparticles are well dispersed. 
However, if the particles are close enough, there is an overlap of the surface plasmon 
vibrations between neighboring particles and results in changes in the optical properties. 
This can occur due to the aggregations of the silver nanoparticles, leading to an 
effective decrease in the average interparticle distance. The absence of higher-
wavelength features indicates the isotropy of the silver nanoparticles, in good agreement 
with Fig. 4. The position and shape of the surface plasmon absorption band is similar to 
those found by other authors [25-27], and indicate a low degree of agglomeration and 
polydispersity of the silver nanoparticles on the HA matrix surface, in agreement with 
the TEM images (Fig. 4). Therefore, the HA matrix acts as an effective scaffold, where 
silver nanoparticles are dispersed, avoiding agglomeration of the nanoparticles. This is 
an important feature, since the small size of silver particles ensures that a significantly 
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large surface area of the particles is in contact with the bacterial effluent. A larger 
contact surface is expected to increase the bactericidal activity. 
To investigate the antibacterial and antifungal effect of the HA/nAg powders, a 
biocide test was performed inoculating 3.6·10
10
 CFU/ml (CFU: colony forming units) of 
Escherichia Coli (gram-negative bacteria), 3.0·10
9
 CFU/ml of Micrococcus Luteus 
(gram-positive bacteria) and 2.2·10
10
 CFU/ml of Issatchenkia Orientalis (yeast). Table 1 
shows the number of colonies (CFU) of E. Coli, M. Luteus and I. Orientalis 
corresponding to control and HA/nAg powder after 24 and 48 h. 
After the exposition time of 24 h, the presence of HA/nAg caused a decrease 
larger than five orders of magnitude in the number of colonies of E. coli, M. luteus and 
I. orientalis. For the three microorganisms, the reduction percentage is above 99.99% 
only in the first 24 h. Finally, no antibacterial activity was found in the silver free media 
that was used as a control. 
 
The logarithm reduction rate (log η) has been used to characterized the 
effectivity of the biocide agent. It was calculated using the number of viable 
microorganisms in the inoculum control and substrate in the Equation 2: 
 
Log η = log A – log B Ec. 2 
 
where A is the average number of microorganisms in the control, B is the average 
number of microorganism in the sample with HA/nAg. The results are shown in Fig. 6.  
The antimicrobial activity tests have revealed that HA/nAg powder is an excellent 
antibacterial agent again Gram-positive and Gram-negative bacterias as well as yeast. 
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These results are similar to those reported by Esteban et al [28] in the case of glass-nAg 
composite powder. In this regard a similar synergetic mechanism between the silver 
nanoparticles and the Ca
2+
 lixiviated from the HA may operates. In Fig. 6, the 
antimicrobial activity of the HA/nAg nanocomposite was compared with a commercial 
broad-spectrum antibacterial/antimicrobial agent using the parameter of the logarithm 
reduction [29]. The result confirm that the composite show an efficacy even higher than 
that of commercial products. This activity of silver against microorganism combined 
with the bioactivity of the matrix place the composite HA/nAg as potential candidate for 
orthopedic and dental applications.  
 
4. Conclusions 
 Silver dispersed nanoparticles have been obtained into a HA matrix following 
a simple low cost bottom-up route. The nanoparticles stay supported on a matrix, 
avoiding agglomeration and health problems and consequently, allowing a better 
manipulation and enhancing their biocide activity. The chemical reduction enables to 
preserve the nanostructured character of the silver and HA phases, avoiding heat 
treatments that can induce grain growth. This nanosized material is comparable to that 
of the bone apatite. 
 In vitro bactericidal activity of HA/nAg was observed against E. coli (Gram-
negative) and M. luteus (Gram-positive). It was achieved a logarithm reduction higher 
than 20, which means a complete safe disinfection. In the case of the yeast (I. orientalis) 
the logarithm reduction is comparable with commercial products, so its antifungal 
activity has been proved. The present work is a contribution to a class of nanomaterials 
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for orthopedic and dental applications combining the bioactivity of HA and the 
additional advantage of silver antimicrobial effects. 
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Figure 1. X-ray diffraction patterns obtained from HA and HA/nAg nanocomposite powders. 
The Bragg’s reflections corresponding to metallic silver have been marked with an asterisk. 
Figure 2. Particle size distribution of the starting HA powders. 
Figure 3. HA/nAg composite SEM image 
Figure 4. TEM micrographs showing the size and morphology of the spherical silver 
nanoparticles attached on the hydroxyapatite surface. Figure 4D was obtained using the 
HAADF technique. 
Figure 5. According to the absorption spectrum of the HA/nAg composite powder (A), the 
light absorption maxima corresponding to the surface plasmon resonance of Ag nanoparticles 
is located at 426 nm. As a consequence, the obtained composite displays the dark greenish 
grey color showed in picture (B). 
Figure 6. Logarithm reduction for E. coli, M. luteus and I. orientalis at 24 and 48 hours (─ ─ 
─ Commercial broad-spectrum antibacterial/antimicrobial). 
Table 1. CFU ml
−1
 of E. coli, M. luteus and I. orientalis corresponding to biocide agents at 0, 
24 and 48 h. 
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E. Coli 
 0h 24h 48h 
Control (CFU/ml) 3,60E+10 1,40E+11 3,00E+11 
HA/nAg (CFU/ml) 3,60E+10 1,00E-04 1,00E-04 
M. Luteus 
 0h 24h 48h 
Control (CFU/ml) 3,00E+09 3,00E+09 1,00E+09 
HA/nAg (CFU/ml) 3,00E+09 1,00E-04 1,00E-04 
I. Orientalis 
 0h 24h 48h 
Control (CFU/ml) 2,20E+10 1,20E+11 4,80E+10 
HA/nAg (CFU/ml) 2,20E+10 1,00E+04 1,00E+05 
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